Brentuximab Vedotin
Molecular Name: Brentuximab Vedotin
Active Ingredient: Brentuximab vedotin
Dosage Form: 150mg / vial
Manufacturer Name:
Why is Brentuximab Vedotin prescribed?
Adcetris is a chemotherapeutic medication that fights cancer (“antineoplastic” or “cytotoxic”) and is available only by prescription.
Patients with Hodgkin’s lymphoma (Hodgkin’s disease) who have not previously had treatment, as well as those who are vulnerable to the condition getting worse or coming back after a stem cell transplant, are treated with injections of brentuximab vedotin together with other chemotherapy medications which is a procedure that replaces diseased bone marrow with healthy bone marrow.
A monoclonal antibody, or kind of protein, found in the Adcetris active ingredient, brentuximab vedotin, binds to CD30 and the cytotoxic (cell-killing) chemical monomethyl auristatin E. To treat leukemias that are CD30-positive, monoclonal antibodies produce monomethyl auristatin E.
The suggested dosage is 1.8 mg/kg given as a 30-minute intravenous infusion every three weeks. Before administering each dose of this medicine, complete blood counts should be checked. Patients need to be examined both during and after an infusion.
Who should not take Brentuximab Vedotin?
- Those who are allergic to any of the ingredients in brentuximab vedotin.
- The patient information sheet's final section includes a detailed list of the constituents in brentuximab vedotin.
- Women who are breastfeeding or pregnant.
- If one has kidney disease that might affect kidney functioning.
If you’re unsure, speak with your doctor.
What are the possible side effects of Brentuximab Vedotin?
- Constipation
- Mouth Sores
- Decreased Appetite
- Weight Loss
- Tiredness
- Dizziness
- Weakness
- Difficulty Falling Asleep or Staying Asleep
- Anxiety
- Dry Skin
- Hair Loss
- Night Sweats
- Joint, Bone, Muscle, Back, Arm, or Leg Pain
- Muscle Spasms
Special Precautions For Kineret
- Brentuximab Vedotin is sold in single dose vials at a reasonable injection cost.
- Brentuximab Vedotin is a sterile, unpreserved fluid for one use only.
- Keep in the refrigerator at 2 to 8 degrees Celsius.
- Avoid freezing.
- To protect against light, keep it in the original container.
- The vial shouldn't be shaken.
- For ambulatory use, Kineret may be left out of the fridge for up to 12 hours at a temperature no higher than 25 °C without going past the expiration date.
- The product must be thrown off once this time has passed instead of returning it to the refrigerator.
- For injections, every single-use vial needs to be reconstituted with 10.5 mL of water to a final concentration of 5 mg/mL.
- ADCETRIS is overfilled by 10% in each vial, resulting in a total reconstituted volume of 11 mL and 55 mg of ADCETRIS per vial.
- Gently swirl the vial to aid dissolution. Do not tremble.
- The reconstituted solution in the vial has a final pH of 6.6 and is clear to faintly opalescent.
- Visually checking the reconstituted solution for foreign particles and/or discoloration is advised.
- If one of these are noticed, kindly throw away the medication.
- Following local legislation, waste and unneeded pharmaceuticals should be disposed of.
About Us
We are a leading pharmaceutical wholesaler, Hayat Alhikmah, situated in Dubai. By providing generic medications, reference listed drugs, name patient import services, and temperature-controlled products simple to access for our consumers, we help them overcome geographic distances.
We offer affordable access to adcetris injection in Dubai with ease and speed. Depending on the customer’s needs, we provide a quality guarantee and shipping anywhere in the world.
Please schedule a consultation with us by calling us at +971 54 777 1238 or email us at [email protected] to know how much Brentuximab Vedotin injection costs in Dubai. Our helpful team would be happy to assist you and provide any general or medical information.
Distributors
Ware House
Awards
FAQ's
A drug used to treat cancer is called brentuximab. Also, it goes by the brand name Adcetris; its full name is brentuximab vedotin. It is a therapy for Hodgkin lymphoma, cutaneous T cell lymphoma, anaplastic large cell lymphoma, and a non-Hodgkin lymphoma subtype. Monoclonal antibodies include brentuximab. These medicines are created in laboratories. These medicines will target specific proteins on the cell surface. Monoclonal antibodies look for cancer cells. Anaplastic large-cell lymphoma and Hodgkin lymphoma cells contain a protein called CD30, the target of the drug brentuximab. To deliver medicine to the cell, brentuximab adheres to the CD30 protein. After that, the medication kills the cell.
For some kids and teenagers with Hodgkin lymphoma, it could be able to curtail or even do away with the need for radiation therapy. In a recent study, the targeted medication brentuximab vedotin was used in place of one chemotherapy agent as the initial treatment for kids and teenagers with a high-risk variant of Hodgkin lymphoma. The adjusted therapy significantly decreased the need for radiation therapy among study participants while being very effective against malignancy. A well-known first or first-line treatment regimen for high-risk juvenile Hodgkin lymphoma was used in the trial. However, brentuximab was used in place of the chemotherapeutic agent vincristine. When necessary, radiation treatment is used after combinations of several chemotherapy medications.
Blood malignancies Hodgkin lymphoma, systemic anaplastic large cell lymphoma, and primary cutaneous anaplastic large cell lymphoma are all treated with the injection of brentuximab. A specialist injects this medicine over 30 minutes into a vein. It is administered as your doctor instructs, typically once every three weeks. Your weight, medical history, and treatment response determine the dosage. Throughout the infusion, your healthcare provider will keep an eye on you if you experience a brentuximab reaction. If a less severe reaction happens, the injection will be stopped, the response will be treated, and the infusion will resume. Depending upon the reaction of the drug, the dosage will be adjusted by your doctor.
Hodgkin lymphoma, systemic anaplastic large cell lymphoma, and primary cutaneous anaplastic large cell lymphoma are all blood malignancies treated by the injection of brentuximab. Patients who underwent unsuccessful cancer treatments, such as bone marrow transplants, are treated with this medicine. Stage III or stage IV classical Hodgkin lymphoma can also be treated with a brentuximab injection and other cancer medications. Patients with sALCL or other peripheral T-cell lymphomas that express CD30 may also receive combination therapy with a brentuximab injection and additional drugs. The proliferation of cancer cells is slowed down by brentuximab, and the body ultimately eliminates them. Only your doctor, acting directly under their direction, may provide this medication.
Adcetris is a chemotherapeutic medication that fights cancer (“antineoplastic” or “cytotoxic”) and is available only by prescription.
Patients with Hodgkin’s lymphoma (Hodgkin’s disease) who have not previously had treatment, as well as those who are vulnerable to the condition getting worse or coming back after a stem cell transplant, are treated with injections of brentuximab vedotin together with other chemotherapy medications which is a procedure that replaces diseased bone marrow with healthy bone marrow.
A monoclonal antibody, or kind of protein, found in the Adcetris active ingredient, brentuximab vedotin, binds to CD30 and the cytotoxic (cell-killing) chemical monomethyl auristatin E. To treat leukemias that are CD30-positive, monoclonal antibodies produce monomethyl auristatin E.
- Those who are allergic to any of the ingredients in brentuximab vedotin.
- The patient information sheet’s final section includes a detailed list of the constituents in brentuximab vedotin.
- Women who are breastfeeding or pregnant.
- If one has kidney disease that might affect kidney functioning.
- Constipation
- Mouth Sores
- Decreased Appetite
- Weight Loss
- Tiredness
- Dizziness
- Weakness
- Difficulty Falling Asleep or Staying Asleep
- Anxiety
- Dry Skin
- Hair Loss
- Night Sweats
- Joint, Bone, Muscle, Back, Arm, or Leg Pain
- Muscle Spasms
Severe possible side effects of Brentuximab Vedotin include:
- Brentuximab Vedotin is sold in single dose vials at a reasonable injection cost.
- Brentuximab Vedotin is a sterile, unpreserved fluid for one use only.
- Keep in the refrigerator at 2 to 8 degrees Celsius.
- Avoid freezing.
- To protect against light, keep it in the original container.
- The vial shouldn’t be shaken.
- For ambulatory use, Kineret may be left out of the fridge for up to 12 hours at a temperature no higher than 25 °C without going past the expiration date.
- The product must be thrown off once this time has passed instead of returning it to the refrigerator.
- For injections, every single-use vial needs to be reconstituted with 10.5 mL of water to a final concentration of 5 mg/mL.
- ADCETRIS is overfilled by 10% in each vial, resulting in a total reconstituted volume of 11 mL and 55 mg of ADCETRIS per vial.
- Gently swirl the vial to aid dissolution. Do not tremble.
- The reconstituted solution in the vial has a final pH of 6.6 and is clear to faintly opalescent.
- Visually checking the reconstituted solution for foreign particles and/or discoloration is advised.
- If one of these are noticed, kindly throw away the medication.
- Following local legislation, waste and unneeded pharmaceuticals should be disposed of.
